Although alpha-fetoprotein (AFP) is a well-known biomarker for HCC, poor sensitivity and specificity resulting from non-secretion by a considerable fraction of HCC tumor cells reduce its therapeutic utility [7,8]. This evidence concerns the gene AFP and hepatocellular carcinoma.